

Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat, India Tel: +91-7045456789 / 7046456789

Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India

Tel: (91-22) 26701050 / 1 / 2 / 3 Email: contact@samratpharmachem.in

July 19, 2021

To,
Department of Corporate Services,
BSE Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Reconciliation of Share Capital Audit f.t.q.e. 30/06/2021

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended June 30, 2021.

Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Nishant Kankaria Company Secretary & Compliance Officer

A. A. MULLA & ASSOCIATES

Company Secretaries

Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp. Kurla Station East, Mumbai – 400 024. M: 9892237418 Email: aqueelmulla@gmail.com

July 19, 2021

The Board of Directors, M/s. Samrat Pharmachem Limited Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended 30th June, 2021, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

MEM. No. 2973

Yours faithfully,

For A.A. Mulla & Associates

Company Secretaries

Aqueel A. Mulla **Proprietor**

UDIN: F002973C000653029

Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details					
1.	For Quarter Ended	30 th June, 2021					
2.	ISIN	INE103E01016					
3.	Face Value	Rs. 10					
4.	Name of the Company	Samrat Pharmachem Limit	ted				
5.	Registered Office Address	Plot No. A2/3445,					
		GIDC, Phase 4,					
		Ankleshwar – 393 002,					
		Gujarat.					
6.	Correspondence Address	701/702, Business Square,					
		M. A. Road,					
		Andheri (West),					
		Mumbai – 400 058.					
7.	Tel No. & Fax No.	Tel : (022) 26701050					
		Fax : (022) 26701053					
8.	Email Address	contact@samratpharmachem.in					
	Website	www.samratpharmachem.com					
9.	Names of the stock exchanges where the	Mumbai					
10	company's securities are listed.	N. C.1	0/ 6/ 1: 1 :/1				
10.	Issued Capital	No. of shares	% of total issued capital				
1.1	T' (1C '(1C 1 W'))	30,89,700	100.00 %				
11.	Listed Capital (Exchange Wise)	20.00.700	100.00.07				
	As per company records	30,89,700 100.00 %					
12	It is same for all the exchanges Held in demonstrational forms in CDSI.	4.50.100					
12.	Held in dematerialized form in CDSL	4,58,108	14.83 %				
13.	Held in dematerialized form in NSDL	22,67,482 73.39 %					
14.	Physical	3,64,110 11.78 %					
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %				
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)		Nil				

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

^{***} Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable



19. Reference of previous quarter with regards to excess de-materialised shares, if any.	
20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?	

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. &	Name	:	Mr. Nishant Anandkumar Kankaria
	Membership No. of the Compliance	Tel No.	:	(91-22) 26701050
	Officer of the Co.	Fax No.	:	-
		Membership No.	:	ACS-59905
		Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No.,	Name	:	A. A. Mulla & Associates
	Regn No. of the Certifying CA/CS			Company Secretaries
		Address	:	Room No.603, A Wing, 6th Floor,
				Dhamm Seva CHS, Deluxe Building,
				Opp Kurla Station East,
				Mumbai-400024
		Tel No.	:	(91) 9892237418
		Membership No.	:	2973
		Email	:	aqueelmulla@gmail.com

24.	Appointment of common agency for	Name	:	Link Intime India Pvt Ltd
	share registry work	Address	:	C-101, 247 Park,
				L. B. S. Marg, Vikhroli (West),
				Mumbai – 400 083, Maharashtra.
		Tel No.	:	(022) 49186000
		Fax No.	:	(022) 49186060
		Email	:	rnt.helpdesk@linkintime.co.in
		Kind Attn	:	Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

Date: July 19, 2021 Place: Mumbai For A. A. Mulla & Associates

Company Secretaries

Aqueel A Mulla Proprietor C.P. No. 3237 CS No. 2973

UDIN: F002973C000653029